Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuri Taniguchi

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2022
A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630Yuri Taniguchi, Tsuneo Shimokawa, Yuichi Takiguchi, et al.
Lung Cancer (Amsterdam, Netherlands)|April 20, 2025
Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for advanced nonsquamous non-small cell lung cancer with impaired renal function: A multicenter, single-arm phase 2 trial (RESTART, LOGiK 2002)Yoshimasa Shiraishi, Takayuki Shimose, Kazunori Tobino, et al.
Anticancer Research|December 3, 2024
Optimal Therapy for Postoperative Recurrence: Does Salvage Radiation Work for Locoregional Recurrence?Yuri Taniguchi, Takao Shigenobu, Akiko Hayashi, et al.
The Journal of Experimental Medicine|July 15, 2025
Monoallelic mutations in MMD2 cause autosomal dominant aggressive periodontitisTomoyuki Iwata, Yoko Mizoguchi, Tetsuya Yoshimoto, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2022
A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630Yuri Taniguchi, Tsuneo Shimokawa, Yuichi Takiguchi, et al.
Lung Cancer (Amsterdam, Netherlands)|April 20, 2025
Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for advanced nonsquamous non-small cell lung cancer with impaired renal function: A multicenter, single-arm phase 2 trial (RESTART, LOGiK 2002)Yoshimasa Shiraishi, Takayuki Shimose, Kazunori Tobino, et al.
Anticancer Research|December 3, 2024
Optimal Therapy for Postoperative Recurrence: Does Salvage Radiation Work for Locoregional Recurrence?Yuri Taniguchi, Takao Shigenobu, Akiko Hayashi, et al.
The Journal of Experimental Medicine|July 15, 2025
Monoallelic mutations in MMD2 cause autosomal dominant aggressive periodontitisTomoyuki Iwata, Yoko Mizoguchi, Tetsuya Yoshimoto, et al.
Pageof 4